Neurological Manifestations in Adult Survivors of Ebola Virus Disease Supplement 1. eTable 1. Summary of components of neurological exam scores eTable 2. Comparison of symptoms at the baseline neurologic evaluation between survivors and contacts eTable 3. Comparison of ongoing symptoms at the baseline neurologic evaluation between survivors and contacts eTable 4. Comparison of neurologic exam scores between survivors and close contacts by neurologic evaluation eTable 5.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Cavan Reilly
Proteomic and Genetic predictors and risk scores of cardiovascular diseases in persons living with HIV
The authors have declared no competing interest. Sandra Safo was partially supported by grant number 1R35GM14269 from NIH. Lillian Haine was supported by the NIH under award number T32HL129956 and in part by the NIH's National Center for Advancing Translational Sciences (NCATS), grants TL1R002493 and UL1TR002494. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Tobacco use, self-reported professional dental cleaning habits, and lung adenocarcinoma diagnosis are associated with bronchial and lung microbiome alpha diversity | Respiratory Research | Full Text
We conducted a prospective observational study of patients undergoing lung lobectomy at the Minneapolis VA Medical Center (MVAMC) for suspected or confirmed lung cancer. To decrease the influence of medications on our findings, we excluded subjects who had used antibiotics or systemic corticosteroids in the prior 1 month. The protocol was approved by the Minneapolis VA IRB (#4348-B) and in accordance of the Declaration of Helsinki.
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Summary Background We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19.
Putting Treatments to the Test
Illnesses like heart disease, HIV, and Ebola kill millions of people every year. Prevention is the first defense against them, but once contracted, reducing their impact largely rests on the development of vaccines and medications that must be proven safe and effective before general use.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Cavan
Contact Cavan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack